Table 3.
Univariable analyses of factors associated with 30-day mortality
| HR (95% CI) | P value | |
|---|---|---|
| Female gender | 1.25 (0.83–1.87) | 0.270 |
| Age | 1.00 (0.98–1.01) | 0.898 |
| Primary tumor site | ||
| Cutaneous squamous-cell carcinoma | (reference) | |
| Gastrointestinal | 1.32 (0.32–5.44) | 0.693 |
| Breast | 1.15 (0.26–5.01) | 0.845 |
| Head and Neck | 2.75 (0.53–14.23) | 0.226 |
| Genitourinary | 0.52 (0.07–3.69) | 0.515 |
| Gynecologic | 1.00 (0.18–5.48) | 0.996 |
| Lung | 0.92 (0.19–4.25) | 0.915 |
| Sarcoma | 0.87 (0.16–4.49) | 0.871 |
| Unknown primary | 0.90 (0.08–9.94) | 0.933 |
| Number of metastatic sites (> 2 vs ≤ 2) | 0.91 (0.66–1.35) | 0.663 |
| Main symptom at hospitalization | ||
| Pain | (reference) | |
| Dyspnea | 1.04 (0.50–2.17) | 0.896 |
| Infection-related symptoms | 1.14 (0.49–2.64) | 0.753 |
| Bleeding/ Symptomatic anemia | 0.53 (0.15–1.90) | 0.336 |
| Gastrointestinal symptoms | 2.04 (1.07–3.88) | 0.029 |
| Neurologic symptoms | 1.79 (0.67–4.78) | 0.243 |
| Fatigue | 1.79 (0.77–4.16) | 0.171 |
| ECOG-PS (3–4 vs 2) | 2.05 (1.17–3.62) | 0.012 |
| Anemia (yes vs no) | 1.05 (0.71–1.55) | 0.792 |
| Leukocytosis (yes vs no) | 1.20 (0.80–1.79) | 0.364 |
| Lymphopenia (yes vs no) | 1.07 (0.72–1.60) | 0.710 |
| Hypercalcemia (yes vs no) | 2.09 (1.20–3.63) | 0.008 |
| Renal impairment (yes vs no) | 1.20 (0.62–2.31) | 0.573 |
| Liver enzymes elevation (yes vs no) | 1.84 (1.17–2.90) | 0.008 |
| Total bilirubin elevation (yes vs no) | 3.07 (1.94–4.84) | < 0.001 |
| Body mass index | ||
| Underweight | (reference) | |
| Normal | 1.07 (0.58–1.97) | 0.810 |
| Overweight | 1.09 (0.52–2.26) | 0.817 |
| Obesity | 1.25 (0.61–2.59) | 0.531 |
| Charlson Index > 6 | 1.27 (0.83–1.94) | 0.253 |
Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance Status, HR hazard ratio, CI confidence interval
1Univariable Cox regression